Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck

被引：7

作者：

Suzuki, Shinsuke ^{[1
]}

Toyoma, Satoshi ^{[1
]}

Tomizawa, Hiroki ^{[1
]}

Yamada, Toshiki ^{[1
]}

Iikawa, Nobuko ^{[1
]}

Shiina, Kazuhiro ^{[1
]}

Saito, Hidekazu ^{[1
]}

Koizumi, Koh ^{[1
]}

Kawasaki, Yohei ^{[1
]}

Yamada, Takechiyo ^{[1
]}

机构：

[1] Akita Univ, Dept Otorhinolaryngol & Head & Neck Surg, Grad Sch Med, Akita 0108543, Japan

来源：

AURIS NASUS LARYNX | 2020年 / 47卷 / 03期

关键词：

Head and neck squamous cell carcinoma; Immune checkpoint inhibitor; Nivolumab; Chemotherapy; Recurrence; Metastasis; INVESTIGATORS CHOICE; RESPONSE RATES; RECURRENT; INHIBITORS; CETUXIMAB; THERAPY; CANCER; TRIAL;

D O I：

10.1016/j.anl.2019.06.004

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided. Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer. However, there are few reports on the increased effect of chemotherapy after nivolumab treatment in SCCHN. Therefore, cases must be accumulated to identify patients with nivolumab-refractory SCCHN who may benefit from chemotherapy. Here, we present patients with SCCHN who exhibited a significant response to chemotherapy after nivolumab treatment. (C) 2019 Elsevier B.V. All rights reserved.

引用

页码：485 / 488

页数：4

共 50 条

[21] When is chemotherapy in head and neck squamous cell carcinoma not indicated?
Missak Haigentz
Jan B. Vermorken
Arlene A. Forastiere
June Corry
Jonathan J. Beitler
Primož Strojan
Dana M. Hartl
Juan P. Rodrigo
Carol R. Bradford
Alessandra Rinaldo
Robert P. Takes
William M. Mendenhall
Ashok R. Shaha
Gregory T. Wolf
Alfio Ferlito
European Archives of Oto-Rhino-Laryngology, 2015, 272 : 781 - 787
[22] Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck
Fanucchi, M
Khuri, FR
SEMINARS IN ONCOLOGY, 2004, 31 (06) : 809 - 815
[23] CHEMOTHERAPY IN ADVANCED HEAD AND NECK SQUAMOUS-CELL CARCINOMA
LEHNERT, M
JAKSE, R
SEEWANN, HL
ONKOLOGIE, 1984, 7 (05): : 297 - 299
[24] CHEMOTHERAPY OF RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
PERRY, MC
DAVIDSON, EM
KARDINAL, CG
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 479 - 479
[25] Induction chemotherapy in the management of squamous cell carcinoma of the head and neck
Roman, Eloy
Raez, Luis E.
Santos, Edgardo S.
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (09) : 1205 - 1215
[26] CHEMOTHERAPY STRATEGIES IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
ALSARRAF, M
CRC CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1984, 1 (04): : 323 - 355
[27] Chemotherapy for squamous cell carcinoma of head and neck: The future is now
Vokes, EE
Athanasiadis, I
ANNALS OF ONCOLOGY, 1996, 7 (01) : 15 - 29
[28] Chemotherapy in locally advanced head and neck squamous cell carcinoma
Gyawali, Bishal
Shimokata, Tomoya
Honda, Kazunori
Ando, Yuichi
CANCER TREATMENT REVIEWS, 2016, 44 : 10 - 16
[29] Chemotherapy in the management of squamous-cell carcinoma of the head and neck
Lamont, Elizabeth B.
Vokes, Everett E.
LANCET ONCOLOGY, 2001, 2 (05): : 261 - 269
[30] The future of induction chemotherapy for head and neck squamous cell carcinoma
Haigentz, Missak, Jr.
Cohen, Ezra E. W.
Wolf, Gregory T.
Strojan, Primoz
Eisbruch, Avraham
Ferlito, Alfio
ORAL ONCOLOGY, 2012, 48 (11) : 1065 - 1067

← 1 2 3 4 5 →